Status:
COMPLETED
Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Lead Sponsor:
HealthPartners Institute
Conditions:
Alzheimer Disease
Eligibility:
All Genders
40-90 years
Phase:
NA
Brief Summary
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion. AD is functionally ch...
Eligibility Criteria
Inclusion
- Established diagnosis of Mild Cognitive Impairment (MCI)/mild AD
- Evidence for Central Nervous System (CNS) amyloidosis (e.g., Amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers consistent with AD)
- Prior brain imaging performed
- Mini-Mental State Examination (MMSE) \>24
- Clinical Dementia Rating (CDR) Scale 0.5-1
- Stable dose of cholinesterase inhibitors and memantine for at least one month
- Subjects are between 40-90 years of age
Exclusion
- Non-AD dementia including, but not limited to, Lewy body dementia, frontotemporal dementia, vascular dementia, Jakob-Creutzfeldt disease, etc.
- Inability to tolerate rs-fMRI
- Contraindication of rs-fMRI due to implants or metal
- Seizure disorder
Key Trial Info
Start Date :
June 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05292222
Start Date
June 17 2022
End Date
November 7 2023
Last Update
January 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HealthPartners Neuroscience Center
Saint Paul, Minnesota, United States, 55130